Download the slides

---

Related articles :

• FLAMINGO
• GS-236-0103
• ACTG A5257
• WAVES
• ARIA

---

Table of contents

Comparison of INSTI vs PI
Study WAVES : EVG/C/FTC/TDF QD vs ATV + r
+ FTC/TDF QD in Women
Original article : Squires K. IAS 2015 Vancouver, Abs. MOLBPE08 ;
Squires K. Lancet HIV 2016; 3(9):e410-e420
Last update : 18/07/2016

Dr Anton Pozniak
Chelsea and Westminster Hospital
London, UK

• EVG/C/FTC/TDF QD was virologically non inferior and superior to ATV + r + FTC/TDF
• Similar virologic response of the 2 regimens in different subgroups of patients, including those with high HIV RNA or CD4 < 350/mm³ at enrolment
• Development of major resistance mutations occurred in
  • No patients on EVG/C/FTC/TDF
  • 3 patients on ATV + r + /FTC/TDF: NRTI mutations, no PI mutations
• Discontinuation because of adverse events was lower with EVG/C/FTC/TDF
• Less incidence of icterus and hyperbilirubinemia with EVG/C/FTC/TDF
• Comparable changes in fasting lipids in both groups, except for total cholesterol which elevation was higher with EVG/C/FTC/TDF
• Median decreases in estimated glomerular filtration rate and in spine and hip BMD were modest and not different between the 2 groups

Design

* Randomisation was stratified by HIV RNA ( ≤ 100,000 or 100,000-400,000 or > 400,000 c/ mL )
at screening and race (black or non-black)

Objective

• Non inferiority of EVG/C/FTC/TDF at W48: % HIV RNA < 50 c/ mL by intention to treat, snapshot analysis (lower margin of the 2-sided 95% CI for the difference = -12%)

Baseline characteristics and patient disposition

Response to treatment at week 48

Mean CD4/mm³ increase at W48 :

• + 221 (EVG/C/FTC/TDF) vs
• + 212 (ATV + r + FTC/TDF)

HIV RNA < 50 c/ mL at W48 by baseline HIV RNA and CD4 count

Emergence of resistance

* Criteria :
- Suboptimal response (HIV RNA ≥ 50 c/ mL and < 1 log₁₀ reduction from baseline by W8, confirmed)
- Virologic rebound (> 400 c/ mL after achieving HIV RNA < 50 c/ mL , or 2 consecutive visits with > 1 log₁₀ increase from nadir)
- HIV RNA > 400 c/ mL at W48
Exclusion of patients with HIV RNA < 50 c/ mL at subsequent visits

Renal and bone mineral density (DXA) assessments

Median change from baseline in fasting lipids (mg/ dL )

Adverse events and Grade 3-4 laboratory abnormalities

 

Back to Table of Contents